View speaker details

Yvonne Wu is the leading partner of Deloitte China Life Sciences and Healthcare (LSHC) industry, and a partner of Deloitte Risk Advisory (RA) department. She joined Deloitte in 1996 and has over 21 years’ experiences in risk management services. Yvonne’s expertise covers risk assessment and solutions, internal audit, internal control, and Contract Risk and Compliance (CRC) services. Yvonne serves many multinational LSHC companies, as well as leading Chinese LSHC companies. Her cross-dimensional experiences together with her rich experiences of business practice in China enable her to provide value added and integrated solutions to her clients. In her role of Deloitte China’s LSHC industry leader, she worked closely with partners across all function and developed a solid industry service team with 600 dedicated Deloitte professionals from all functions of full service breadth and capacity. She is also strongly allied with key stakeholders including government sectors, company executives, industry associations and investors.

View speaker details

Prof. Cai is the Director of Center for Healthcare Management and Policy and Adjunct Professor of Economics at China Europe International Business School (CEIBS). He has been involved in teaching, research and consulting work at universities, consulting firms and government in the area of healthcare over twenty years in both U.S. and China. He has published extensively in the areas of health economics and health policy. He participated in the design, implement and evaluation of the first comprehensive health care reform plan (Massachusetts) in the U.S. and was also actively involved in design of the new health care reform plan in China.

Prof. Cai was the cofounder of the Institute of Economic Development and Business School at the East China University of Science and Technology (Shanghai) and the first Chair of Department of Public Economics at Fudan University. He received 1990 Sun Yie-fang National Economic Science Prizes-Best Paper Award, 2002 Most Outstanding Abstract Award by AcademyHealth in the US, and 2009 Excellent Paper Award from Shanghai Social Science Annual Conference. He received Ph.D. in Public Policy from the Heller School for Social Policy and Management at Brandeis University in 1997 (US), his MA in Economics at Fudan University in 1984 and his BA in Economics at East China Normal University in 1982.

View speaker details

Helen Chen is a Managing Director of L.E.K. Consulting based in Shanghai. She is the head of the China office and sat on L.E.K.’s Global Leadership Team, the firm’s governing board, since 2012. Helen has over 25 years of consulting and industry experience in the U.S. and Asia, and has resided in China since 2000.

Helen is the head of L.E.K.’s China life sciences practice, with extensive case work and industry experience covering the full biopharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness.

She is a frequent speaker and author on the opportunities and issues in the China healthcare and life sciences, and has been quoted by publications including BioCentury, BioWorld, In Vivo, Wall Street Journal, Financial Times and Forbes Asia.

Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech and a sales planner at Abbott Laboratories. She is on the organising committee for the Medtronic Sequoia Fund, and was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997.

View speaker details

Clarissa SHEN had been Sanofi China Head for Global Ethics and Business Integrity function since Feb. 2012. Her main responsibilities are to partner with Sanofi China Country Chair to ensure the affiliate’s business operation to the company’s highest ethical standards. Since Oct. 2020, Clarissa has taken up a new role as Head of EBI China Strategic Competence Development in ensuring that the E&BI department incorporates compliance risk areas across its disciplines and foster the competencies development of China team. Between 2017 and 2019, Clarissa has co-chaired the Compliance Working of RDPAC (An industry association, affiliated to CAEFI, consists of 42 Pharma MNCs), where she won the award of 2018 RDPAC Code & Ethics Ambassador and 2019 RDPAC Best Contributor. In 2020, Clarissa acted as the keynote speaker for Post Covid-19 Compliance Conference for Healthcare Industry in China (financially sponsored by the World Bank for a Siemen’s Global Compliance Program, centred at East China Normal University), on behalf of RDPAC and its member Sanofi.

In 2017, Clarissa co-authored an article of “An Overview of Compliance in China – the Pharma Sector”, which was published by the German HAUFE. The book is entitled as “Governance, Risk and Compliance Management in China”.

Clarissa has been a Board member for European Union Chamber of Commerce (EUCCC) Shanghai Chapter since Mar. 2016. During 2017 EU Delegation Tour to Brussels, Clarissa, in team with EUCCC China President and RDPAC Managing Director participated a high-level dialogue with EU DG SANTE Commissioner Vytenis Andriukaitis and his team, to have exchanged views on Rare Disease Reimbursement Policy and Business Ethic.

Apart from Sanofi, Clarissa has 20+ years’ business and people management experiences in terms of customer service/demand planning/business operation/credit and supply chain management/distributorship management with BMS, Eli Lilly and Ciba Specialty Chemicals.

Clarissa holds a bachelor’s degree from Shanghai University and an MBA degree from University of Canterbury, New Zealand. In year 2019, she was nominated as the first International Board member for Canterbury MBA association.

View speaker details

Ms. Li Ye is leading the Merck China Corporate Affairs hub in support to all the three business sectors (healthcare, life science & performance materials) of Merck in China since January 2018. The China hub is among the 3 regional corporate affairs hubs (Europe, the United States and China) of Merck KGaA globalwide. She is the member of the leadership team of Merck global corporate affairs and sits in the Country Council of Merck in China.

Ms. Li Ye is a veteran in corporate affairs and government relations for international companies with her 20+ years’ working experience. She joined Merck healthcare in August 2013, responsible for the government relations and market access. Prior to that, she had been taking the management roles on government affairs, market access and strategic development in top
international companies including Hoechst, GlaxoSmithKline, Bayer and AstraZeneca, etc. She went to Singapore as the Regional Market Access Lead in Bayer South East Asia in 2008. Later she became Regional Payer Capabilities Director and Global Pricing and Market Access Director for Oncology at AstraZeneca’s Asia Pacific Office until she returned to China.

Li Ye graduated from University of International Business and Economics in Beijing, then she went to the UK for further study. She obtained a master’s degree in Business Administration from the University of Westminster, London. She also holds a Diploma of Economic Evaluation and Assessment in Health from the University of York, UK. In 2016, Li Ye completed her
Executive MBA study in Peking University National Development School in Beijing. She is now studying for a doctorate on financial management run by the National Development School of Peking University and Fordham University in the United States.

As an opinion leader in the industry, Li Ye also holds the positions in 2019 including：
 Vice Chair of the China Association of Enterprises with Foreign Investment (CAEFI)
 Vice Chair of the China Pharmaceutical Industry Association (CPIA)
 National Chair of Pharmaceutical Working Group, European Chamber of Commerce in
China (EUCCC)

View speaker details

Dr. Xuan Cui is the Head of Strategic Access, Pricing and Policy, Public Affairs & Market Access of Sanofi China. He has 7-year experience in market access, pricing, policy research and government affairs in multinational pharmaceutical companies. Before joining Sanofi, Xuan also served in Xi'an Janssen in policy research and government affairs. He also worked in the Regulation and Policy Research Bureau of the Ministry of Health and was a research fellow at the National School of Development, Peking University.

Dr. Xuan Cui holds M.D degree in Ophthalmology and Vision Science at Peking University as well as B.A. degree in Economics and B.S. degree in Medicine at Peking University.

View speaker details

After an extensive career, including, among others, the roles of Global Marketing Director and Country Manager Italy, Mr Canepa moved to China in 2013, and he is presently responsible for the mainland and Hong Kong business of Bracco, an Italian Healthcare Group, specialized in contrast agents for diagnostic imaging and related medical devices.Mr Canepa manages the three Chinese companies of the Group (two affiliates and a JV), accounting for about 1.6 billion RMB and employing more than four hundred people, including R&D, business development, medical and regulatory, production, distribution, promotion, and sales.The largest among the three companies, BraccoSine, is presently expanding its presence in China, with the construction of a new production plan in Pudong (Shanghai), with an investment of more than 300 million RMB.Mr Canepa is a strong supporter of the cooperation between China and Italy, and he has been Vice President of the China-Italy Chamber of Commerce (CICC) for six years and among the founders of the Healthcare Working Group of the CICC of which he is presently the coordinator.He is a strong believer of the social responsibility of companies, and he is personally leading several ESG driven initiatives of the Bracco Group in China. Among them the support to schools in rural areas of China, with donation of computers and the creation of a “Bracco” library, and the Volunteer Day during which the company employees dedicated one day to environmentally and socially relevant causes.In 2022 he has been awarded the Silver Magnolia Award by the Shanghai government.

View speaker details

Frank Zhu, Head of Patents Shanghai at Roche, is responsible for Roche's patent affairs in China since 2011. He is also a member of the Patent Leadership Team at Group Patents since 2013. From 2005 to 2010, he was the project manager and portfolio manager at Roche R&D Center (China) Ltd. Before joining Roche, he was an engineer at Shanghai R&D Center for Polymer Materials, where he was engaged in research and development of silicone materials. He holds a master degree of polymer material and is a qualified patent attorney.

View speaker details

Passion for people and creativity, well balanced wisdom and thrive for excellence, Gu Bin has rich and successful working experience in healthcare including 4 years psychiatrist, 18 years in Lilly China took various leadership position from marketing head, VP Diabetes franchise, Elanco GM.

In July 2014, Gu Bin founded HMS (Healthcare Management Solution), a mobile health start up, support young talents to bring mobile health solution DaTangYi empower physicians to provide better diabetes care to their patients.　

In Oct 2016, Gu Bin founded GB consulting (极北咨询), focus on providing coaching and advisory service to senior executive, team and young talent to unleash their creative leadership potential to achieve more in health care.